With the new licence, generic manufacturers and other companies based anywhere in the world can develop, manufacture and sell low cost, paediatric versions of raltegravir in countries where 98 percent of children with HIV in the developing world live
The Medicines Patent Pool (MPP) announces a collaboration with the University of Liverpool and a licence for the university’s Solid Drug Nanoparticle (SDN) technology to accelerate the development of WHO-recommended antiretrovirals as nanomedicines
UAEM European Conference
MPP’s Advocacy Officer will be presenting on Sunday 1 May
One licence for a HCV medicine, two new disease areas, four new board members, $120 million in savings: check out MPP’s January newsletter for an update on top initiatives in Q3/Q4 2015.
Greg Perry and Philippe Douste-Blazy in Global Health and Diplomacy Magazine